Catalyst Biosciences to Present at the Cantor Global Healthcare Conference
26 sept. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst...
Catalyst Biosciences to Present at the 2019 ASBMB Symposium on Serine Proteases in Pericellular Proteolysis and Signaling Conference
05 sept. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the 2019 American Society for Biochemistry and...
Catalyst Biosciences Announces Transition of Chief Financial Officer
29 août 2019 16h55 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that its chief financial officer, Fletcher Payne, will be stepping down from...
Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summit
16 août 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the Second Annual 2019 Hemophilia Drug Development...
Catalyst Biosciences to Host Key Opinion Leader Meeting on Next-Generation Subcutaneous Factor VIIa Marzeptacog Alfa (Activated) in Patients with Bleeding Disorders on August 15
08 août 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that it will host a Key Opinion Leader (KOL) meeting on next-generation...
Catalyst Biosciences Reports Second Quarter 2019 Operating & Financial Results and Provides a Corporate Update
01 août 2019 08h00 HE
|
Catalyst Biosciences, Inc.
Phase 2 trial of subcutaneously administered MarzAA met primary endpoint of reduction in annualized bleed rate demonstrating safety and clinical efficacy, with >90% reduction in bleeding DalcA...
Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors
08 juil. 2019 05h00 HE
|
Catalyst Biosciences, Inc.
Subcutaneous MarzAA (FVIIa) prophylaxis reduced the annualized bleeding rate by more than 90% compared with pretreatment Data presented at the 2019 Congress of the International Society on Thrombosis...
Catalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and Haemostasis
01 juil. 2019 08h00 HE
|
Catalyst Biosciences, Inc.
Oral presentation of the final Phase 2 trial data of MarzAA for the treatment of hemophilia A or B with inhibitors Company to host investor call and webcast on Monday, July 8 at 8:00 a.m. EDT SOUTH...
Catalyst Biosciences to Present at the Jefferies 2019 Global Healthcare Conference
28 mai 2019 08h00 HE
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst...
Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update
02 mai 2019 08h00 HE
|
Catalyst Biosciences, Inc.
Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019 MarzAA Orphan Drug Designation received from the European...